CA-NEXON-AMERICA
Today, leading game publisher Nexon announced its venerable free-to-play fantasy MMORPG Mabinogi will be celebrating its 14th anniversary on March 27. Players will be able to engage in celebratory bonuses and activities for the game’s anniversary through April 14. As part of continuing quality of life improvements, Mabinogi will also be merging servers on April 14, so that global players can continue to embark on mystical adventures together.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220324005803/en/
The 14th anniversary celebration will include an abundance of updates from equipment repair cost reduction to 20% of the original price to Crom Bás dungeon polishing such as increased drop rate and overall dungeon length reduction. Additionally, the celebration brings a range of prizes, new missions and quests, starting on March 17, including:
- 14th Anniversary Night Bazaar - Meet Dero the Eventsman near Festia’s Main Gate and register your main character to participate in this guide quest, receive prizes, and play mini-games. Plus, all characters will be able to receive a 14th Anniversary Check design when issuing a check from the Tir Chonaill bank.
-
14th Anniversary Quests
-
Bazaar Experience
- This achievement quest rewards players with a special Festival Souvenir Hebona Robe sewing pattern with the opportunity to win a Festival Commemorative Luxury Equipment Bag Box, 20,000 EXP, and 25 instant prize tickets after completing all objectives.
- Daily Quests: Finding Fruitful Fulfillment - Every day brings a different task for players to compete around the Night Bazaar for rewards. Players will be able to receive Cotton Candy from the Dessert Merchant, play in a variety of mini-games, and embark on great adventures by entering the Cave of Trials.
-
Bazaar Experience
- This achievement quest rewards players with a special Festival Souvenir Hebona Robe sewing pattern with the opportunity to win a Festival Commemorative Luxury Equipment Bag Box, 20,000 EXP, and 25 instant prize tickets after completing all objectives.
- 14th Anniversary Hotdays - Players will be able to receive a special 14th Anniversary On-Time Gift Box every week and receive 10 Night Bazaar Stickers every weekend on Saturday and Sunday by logging in during the event.
- Festia Instant Prize Event - Try your luck at the Capsule Machine, located next to Fez in Festia, to open the Instant Prize window with 20,000 gold or one Instant Prize Ticket, which can be gained by participating in certain 14th Anniversary events.
On the heels of the 14th anniversary celebratory activities, players should expect Mabinogi servers to fully integrate on April 14. A new server, Erinn, will be launched on this date. It’s an exciting time to join the world of Mabinogi !
For more information on Mabinogi’s 14th anniversary and server merge, visit the official website and follow @mabinogi on Facebook for the latest updates.
Assets: Anniversary image | Server Merge image
Social Media: Facebook / Twitter / Instagram / Twitch / YouTube / Discord
About Mabinogi http://mabinogi.nexon.net/
Released in 2008, Mabinog i is an immersive free-to-play MMORPG world where mystical adventures await. Create anime-inspired heroes with thousands of customization options, such as hairstyles, facial features and outfits. Select from dozens of talents ranging from professional gunslingers and archers to musicians, tailors and cooks. Players can enjoy the game on their own terms, taking the perilous path of an adventurer or build a thriving business using unique trade skills.
About Nexon America Inc. https://www.nexon.com/
Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005803/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Natus Sensory Appoints Arne Boye Nielsen to Board of Directors8.1.2026 08:00:00 CET | Press release
Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen to its Board of Directors, effective January 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107392331/en/ Arne Boye Nielsen Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades. During his tenure, Arne played a central role in shaping Demant Diagnostics’ long-term strategy, portfolio expansion, and international growth, establishing it as a cornerstone of Demant’s global healthcare footprint. In addition to his executive leadership background, Arne brings extensive board experience. His deep expertise across diagnostics, governance, and value creation will further strengthen Natus Sensory’s Board as the company contin
4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 07:30:00 CET | Press release
FDA IND clearance enabling the worldwide expansion of the INFLAM MOTION Phase 2a trial, involving major U.S. sites Advancing the first clinical proof of concept in OA with a first-in-class intra-articular GLP-1 agonist A holistic clinical strategy design establishing the foundation for a future accelerated approval pathway 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. F
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo®in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 07:30:00 CET | Press release
The agreement builds on Organon’s cardiovascular disease portfolio, leveraging expertise to expand access to new treatments for patients with dyslipidemia, especially statin-intolerant patients.This collaboration addresses a critical gap in care that disproportionately affects women, who are at a 47% higher risk of developing statin intolerance compared to men.i Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnie
Prodapt Earns ISO 42001 Certification, the New Global Benchmark for Responsible Enterprise AI8.1.2026 07:00:00 CET | Press release
Prodapt today announced that it has been awarded the ISO 42001 certification, the world’s first and the only global standard for AI Management Systems (AIMS). Marking a significant milestone in its journey, Prodapt is setting a higher benchmark to deliver secure, ethical, and scalable AI for global enterprises. ISO 42001 lays a rigorous framework for governing AI across strategy, technology, and operations. The certification, awarded by an independent accredited body, validates Prodapt’s enterprise-grade AI management framework, including executive-led oversight, strong technology foundations, and disciplined operational processes. These measures ensure AI systems are responsibly designed, deployed, monitored, and evolved throughout their lifecycle. The evaluation emphasizes risk management, ethical AI practices, transparency, and scalability, confirming Prodapt’s ability to proactively identify and mitigate risks while ensuring accountability in AI-driven outcomes. Human-in-the-loop c
Azafaros to Present at J.P. Morgan’s 44th Annual Healthcare Conference8.1.2026 07:00:00 CET | Press release
Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan’s 44th Annual Healthcare Conference on Thursday, January 15. The company’s presentation will begin at 9:30 am PT/12:30 am ET/6:30 am CET. The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with neurological involvement including GM1/GM2 gangliosidoses and Niemann-Pick type C disease ((NPC). Two pivotal Phase 3 studies investigating nizubaglustat in GM1/GM2 gangliosidoses and NPC are currently enrolling, with data expected in 2027. The studies build on positive data from a robust clinical program including the Phase 2 RAINBOW study and the PRONTO natural history study. The Phase 3 studies are financed following the company’s successful completion of €132 million series B round completed in 1H 2025. About nizubaglust
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom